US niche generics specialist Teligent is at a loss to explain why its share price has tumbled in recent times as it ramps up production at an expanded injectables facility.
US niche generics specialist Teligent Inc. is unable to explain why its share price suddenly plummeted below $1.00, before bouncing back to $1.03 as of midday on 15 April.
“Teligent acknowledges that there have been significant negative movements in the value of our stock over the past many days....
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
